Skip to Content

Movantik Approval History

  • FDA approved: Yes (First approved September 16th, 2014)
  • Brand name: Movantik
  • Generic name: naloxegol
  • Dosage form: Tablets
  • Company: AstraZeneca
  • Treatment for: Constipation

Movantik (naloxegol) is a peripherally-acting mu-opioid receptor antagonist indicated for the treatment of opioid-induced constipation.

Development History and FDA Approval Process for Movantik

Sep 16, 2014Approval FDA Approves Movantik (naloxegol) for Opioid-Induced Constipation
Jun 11, 2014FDA Advisory Committee to Discuss Peripherally-Acting Opioid Receptor Antagonists
Nov 19, 2013New Drug Application for Naloxegol Accepted by United States Food and Drug Administration
Feb 26, 2013AstraZeneca Announces Results From Long-Term Safety Trial Of Naloxegol In Patients With Opioid-Induced Constipation

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.